ZC3H12B

Summary

ZC3H12B (zinc finger CCCH-type containing 12B, HGNC:17407) is a protein-coding gene on chromosome Xq11.2-q12, encoding Probable ribonuclease ZC3H12B (Q5HYM0). May function as RNase and regulate the levels of target RNA species.

The protein encoded by this gene belongs to a family of CCCH-type zinc finger proteins that are involved in the proinflammatory activation of macrophages. The exact function of this family member is unknown, but it is thought to function as a ribonuclease.

Source: NCBI Gene 340554 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism spectrum disorder (Limited, GenCC)
• Clinical variants (ClinVar): 110 total — 2 pathogenic
• MANE Select transcript: NM_001010888

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17407
Approved symbol	ZC3H12B
Name	zinc finger CCCH-type containing 12B
Location	Xq11.2-q12
Locus type	gene with protein product
Status	Approved
Aliases	MCPIP2
Ensembl gene	ENSG00000102053
Ensembl biotype	protein_coding
OMIM	300889
Entrez	340554

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000338957, ENST00000617377, ENST00000696368, ENST00000696369, ENST00000696370, ENST00000888353, ENST00000916775

RefSeq mRNA: 1 — MANE Select: NM_001010888 NM_001010888

CCDS: CCDS48131

Canonical transcript exons

ENST00000338957 — 10 exons

Exon	Start	End
ENSE00000671933	65499883	65499989
ENSE00001610122	65498999	65499233
ENSE00001614677	65497132	65497271
ENSE00001633196	65488646	65489409
ENSE00003967159	65075844	65075912
ENSE00003967164	65366638	65366766
ENSE00003967165	65368829	65368998
ENSE00003967169	65034826	65035269
ENSE00003967171	65501789	65507887
ENSE00003967172	65398593	65398704

Expression profiles

Bgee: expression breadth ubiquitous, 177 present calls, max score 79.88.

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	79.88	silver quality
prefrontal cortex	UBERON:0000451	75.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.22	gold quality
cardiac muscle of right atrium	UBERON:0003379	74.24	gold quality
left ventricle myocardium	UBERON:0006566	74.02	gold quality
cortical plate	UBERON:0005343	73.44	gold quality
Brodmann (1909) area 23	UBERON:0013554	73.11	gold quality
superior frontal gyrus	UBERON:0002661	72.77	gold quality
primary visual cortex	UBERON:0002436	72.66	gold quality
frontal cortex	UBERON:0001870	72.38	gold quality
postcentral gyrus	UBERON:0002581	72.03	gold quality
neocortex	UBERON:0001950	71.82	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	71.79	gold quality
middle temporal gyrus	UBERON:0002771	71.69	gold quality
entorhinal cortex	UBERON:0002728	71.58	gold quality
endothelial cell	CL:0000115	71.38	gold quality
calcaneal tendon	UBERON:0003701	71.37	gold quality
cerebral cortex	UBERON:0000956	71.27	gold quality
Brodmann (1909) area 46	UBERON:0006483	71.26	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	71.13	gold quality
Brodmann (1909) area 9	UBERON:0013540	71.00	gold quality
deltoid	UBERON:0001476	70.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	70.41	silver quality
occipital lobe	UBERON:0002021	70.39	gold quality
parietal lobe	UBERON:0001872	69.93	gold quality
anterior cingulate cortex	UBERON:0009835	69.86	gold quality
Ammon’s horn	UBERON:0001954	69.82	gold quality
myocardium	UBERON:0002349	69.72	gold quality
forebrain	UBERON:0001890	69.52	gold quality
nucleus accumbens	UBERON:0001882	69.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.17

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

275 targeting ZC3H12B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6740-5P	100.00	65.64	932
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371A-3P	99.99	66.77	91

Literature-anchored findings (GeneRIF, showing 3)

• MCPIP1, 2, 3, and 4, encoded by four genes, Zc3h12a, Zc3h12b, Zc3h12c, and Zc3h12d, respectively, regulates macrophage activation. (PMID:18178554)
• Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information through Summary Statistics. (PMID:32961112)
• The homeostatic function of Regnase-2 restricts neuroinflammation. (PMID:36753401)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	zc3h12b	ENSDARG00000062463
mus_musculus	Zc3h12b	ENSMUSG00000035045
rattus_norvegicus	Zc3h12b	ENSRNOG00000011508
drosophila_melanogaster	Regnase-1	FBGN0038769
drosophila_melanogaster	CG42360	FBGN0259742
caenorhabditis_elegans		WBGENE00013107
caenorhabditis_elegans	rege-1	WBGENE00016260
caenorhabditis_elegans		WBGENE00021287
caenorhabditis_elegans		WBGENE00021998
caenorhabditis_elegans		WBGENE00022003

Paralogs (6): KHNYN (ENSG00000100441), N4BP1 (ENSG00000102921), ZC3H12C (ENSG00000149289), ZC3H12A (ENSG00000163874), ZC3H12D (ENSG00000178199), NYNRIN (ENSG00000205978)

Protein

Protein identifiers

Probable ribonuclease ZC3H12B — Q5HYM0 (reviewed: Q5HYM0)

Alternative names: MCP-induced protein 2, Zinc finger CCCH domain-containing protein 12B

All UniProt accessions (3): Q5HYM0, A0A8Q3WL71, A0A8Q3WM69

UniProt curated annotations — full annotation on UniProt →

Function. May function as RNase and regulate the levels of target RNA species.

Similarity. Belongs to the ZC3H12 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5HYM0-1	1	yes
Q5HYM0-2	2

RefSeq proteins (1): NP_001010888* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000571	Znf_CCCH	Domain
IPR021869	RNase_Zc3h12_NYN	Domain
IPR040546	Rege-1_UBA-like	Domain
IPR040757	Regnase_1/ZC3H12_C	Domain
IPR051101	ZC3H12/N4BP1_RNase_Reg	Family

Pfam: PF11977, PF18039, PF18561

UniProt features (30 total): strand 11, helix 8, compositionally biased region 4, turn 2, chain 1, domain 1, zinc finger region 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6SJD	X-RAY DIFFRACTION	3.29

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5HYM0-F1	59.19	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 108 (showing top): GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, TAATAAT_MIR126, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOMF_NUCLEASE_ACTIVITY, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, CTCTAGA_MIR526C_MIR518F_MIR526A, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, CAGCAGG_MIR370, GOMF_RNA_ENDONUCLEASE_ACTIVITY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, AGCTCCT_MIR28, ATGTTTC_MIR494

GO Biological Process (0):

GO Molecular Function (7): mRNA binding (GO:0003729), RNA endonuclease activity (GO:0004521), zinc ion binding (GO:0008270), hydrolase activity (GO:0016787), nuclease activity (GO:0004518), endonuclease activity (GO:0004519), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasmic ribonucleoprotein granule (GO:0036464)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA binding	1
endonuclease activity	1
RNA nuclease activity	1
transition metal ion binding	1
catalytic activity	1
catalytic activity, acting on a nucleic acid	1
nuclease activity	1
cation binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
ribonucleoprotein granule	1

Protein interactions and networks

STRING

266 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZC3H12B	RC3H2	Q9HBD1	538
ZC3H12B	RC3H1	Q5TC82	464
ZC3H12B	TJAP1	Q5JTD0	434
ZC3H12B	ZC3H8	Q8N5P1	395
ZC3H12B	ZC3HAV1L	Q96H79	391
ZC3H12B	SARNP	P82979	388
ZC3H12B	LARP4B	Q92615	386
ZC3H12B	MTMR8	Q96EF0	368
ZC3H12B	ZFP36	P26651	355
ZC3H12B	THOC3	Q96J01	343
ZC3H12B	RBM26	Q5T8P6	338
ZC3H12B	LENG9	Q96B70	334
ZC3H12B	ZC3H7A	Q8IWR0	320
ZC3H12B	SMG6	Q86US8	316
ZC3H12B	ZC3H15	Q8WU90	314

IntAct

2 interactions, top by confidence:

A	B	Type	Score
FMR1	ZC3H12B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (3): ZC3H12B (Affinity Capture-MS), IL6 (Affinity Capture-RNA), IER3 (Affinity Capture-RNA)

ESM2 similar proteins: A0JPN4, A2A288, A2ARK0, A6ND36, A6QQJ8, A7E316, E9Q0S6, E9Q2Z1, O15037, O54714, O54967, O70260, O70405, O75385, O94983, P42335, P48778, Q07912, Q0P4K8, Q17R13, Q1LVK9, Q32PJ7, Q4V8I3, Q5D1E7, Q5D1E8, Q5DTV4, Q5HYM0, Q5JV73, Q5SWY7, Q5SXM2, Q5U2X5, Q5XIS1, Q68CZ2, Q6A037, Q6IRU7, Q6P1H6, Q6S5L8, Q7TP65, Q7TSG2, Q80U38

Diamond homologs: A0JPN4, A2A288, A6QQJ8, O15037, O75113, Q1LVK9, Q5D1E7, Q5D1E8, Q5DTV4, Q5DTZ0, Q5HYM0, Q5ZLE9, Q6A037, Q6DJS0, Q7ZXG4, Q80U38, Q8BIY3, Q95YE2, Q9C0D7, Q9P2P1, A6NKG5, Q8I7P9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

110 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	50
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3571456	GRCh38/hg38 Xq11.2(chrX:64951692-65166933)x1	Pathogenic
978034	NC_000023.11:g.64951692_65166933del	Pathogenic

SpliceAI

894 predictions. Top by Δscore:

Variant	Effect	Δscore
X:65489391:G:GT	donor_gain	1.0000
X:65497118:T:TA	acceptor_gain	1.0000
X:65497121:A:AG	acceptor_gain	1.0000
X:65497122:T:G	acceptor_gain	1.0000
X:65497130:A:G	acceptor_gain	1.0000
X:65497267:TACAG:T	donor_loss	1.0000
X:65497268:ACAG:A	donor_loss	1.0000
X:65497269:CAGGT:C	donor_loss	1.0000
X:65497270:AGGT:A	donor_loss	1.0000
X:65497271:GG:G	donor_loss	1.0000
X:65497272:G:C	donor_loss	1.0000
X:65497273:T:A	donor_loss	1.0000
X:65499183:G:GT	donor_gain	1.0000
X:65499186:G:GT	donor_gain	1.0000
X:65499200:A:T	donor_gain	1.0000
X:65499234:G:GG	donor_gain	1.0000
X:65499272:G:GG	donor_gain	1.0000
X:65499986:TATGG:T	donor_loss	1.0000
X:65499987:ATGG:A	donor_loss	1.0000
X:65499988:TGG:T	donor_loss	1.0000
X:65499989:GGTG:G	donor_loss	1.0000
X:65499990:G:GA	donor_loss	1.0000
X:65499991:T:G	donor_loss	1.0000
X:65499992:GAG:G	donor_loss	1.0000
X:65489408:AGGT:A	donor_loss	0.9900
X:65489410:G:GC	donor_loss	0.9900
X:65489411:T:G	donor_loss	0.9900
X:65497114:A:AG	acceptor_gain	0.9900
X:65497114:ATTCT:A	acceptor_gain	0.9900
X:65497115:T:G	acceptor_gain	0.9900

AlphaMissense

5563 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:65489154:T:C	L118P	1.000
X:65489226:T:C	L142S	1.000
X:65489235:T:C	L145P	1.000
X:65489379:T:A	V193D	1.000
X:65489382:T:A	V194D	1.000
X:65489387:G:C	D196H	1.000
X:65489388:A:C	D196A	1.000
X:65489388:A:G	D196G	1.000
X:65489388:A:T	D196V	1.000
X:65489389:T:A	D196E	1.000
X:65489389:T:G	D196E	1.000
X:65489390:G:A	G197R	1.000
X:65489390:G:C	G197R	1.000
X:65489391:G:A	G197E	1.000
X:65489391:G:T	G197V	1.000
X:65489393:A:C	S198R	1.000
X:65489395:T:A	S198R	1.000
X:65489395:T:G	S198R	1.000
X:65489396:A:G	N199D	1.000
X:65489398:T:A	N199K	1.000
X:65489398:T:G	N199K	1.000
X:65489400:T:A	V200E	1.000
X:65489403:C:A	A201E	1.000
X:65497133:C:G	H204D	1.000
X:65497136:G:T	G205W	1.000
X:65497137:G:A	G205E	1.000
X:65497137:G:T	G205V	1.000
X:65497143:A:T	K207I	1.000
X:65497151:T:C	F210L	1.000
X:65497152:T:C	F210S	1.000

dbSNP variants (sampled 300 via entrez): RS1000001727 (X:65410472 A>C), RS1000014720 (X:65456048 G>A), RS1000015774 (X:65222706 C>T), RS1000024386 (X:65452860 A>C), RS1000026515 (X:65075103 C>A), RS1000031975 (X:65035398 C>G), RS1000035082 (X:65279515 A>G), RS1000036286 (X:65119171 C>G,T), RS1000037604 (X:65171541 C>T), RS1000047548 (X:65333146 A>C), RS1000049797 (X:65074928 A>G), RS1000050061 (X:65154364 T>A,G), RS1000058686 (X:65071236 G>A), RS1000062080 (X:65262119 C>G), RS1000063936 (X:65272136 C>G,T)

Disease associations

OMIM: gene MIM:300889 | disease phenotypes: MIM:301041

GenCC curated gene-disease

Disease	Classification	Inheritance
autism spectrum disorder	Limited	Autosomal dominant

Mondo (2): Wieacker-Wolff syndrome, female-restricted (MONDO:0026762), autism spectrum disorder (MONDO:0005258)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	decreases expression, affects cotreatment	2
Valproic Acid	decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cisplatin	decreases expression, affects cotreatment	1
Estradiol	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vanadates	decreases expression	1
Aflatoxin M1	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2PF	HAP1 ZC3H12B (-) 1	Cancer cell line	Male
CVCL_E2PG	HAP1 ZC3H12B (-) 2	Cancer cell line	Male
CVCL_E2PH	HAP1 ZC3H12B (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder